Expert Ratings for Werewolf Therapeutics
Within the last quarter, Werewolf Therapeutics (NASDAQ:HOWL) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Recap: Werewolf Therapeutics Q1 Earnings
Werewolf Therapeutics (NASDAQ:HOWL) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:00 AM. Here’s what…
Werewolf Therapeutics Publishes Preclinical Data On mWTX-330, An IL-12 INDUKINE™ Molecule, In Cancer Immunology Research
Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the
Werewolf Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q4, Werewolf Therapeutics‘s (NASDAQ:HOWL) reported sales totaled $7.28 million. Despite a…
Analyst Ratings for Werewolf Therapeutics
Werewolf Therapeutics (NASDAQ:HOWL) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 167 companies set new 52-week lows.
EF Hutton Initiates Coverage On Werewolf Therapeutics with Buy Rating, Announces Price Target of $8.3
EF Hutton analyst Michael King initiates coverage on Werewolf Therapeutics (NASDAQ:HOWL) with a Buy rating and announces Price Target of $8.3.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 160 companies set new 52-week lows.
